Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • Malaria, vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D and Introduction
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
        • The decision-making framework for malaria vaccines
        • Economic analysis
        • Public health impact analysis
        • Sociocultural research
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Malaria, vaccines & biologics
    • Need for vaccines
      • Malaria vaccine roadmap
      • Preferred product characteristics
    • Malaria parasite life cycle
  • R&D and Introduction
    • First-generation vaccines
    • Next-generation vaccines
      • Pre-erythrocytic vaccine candidates
      • Blood-stage vaccine candidates
      • Transmission-blocking vaccine candidates
      • Combination vaccine candidates
    • Monoclonal antibodies
  • RTS,S
  • Access
    • Preparing for malaria vaccine decisions
      • Global policy and regulatory pathways
      • Decision-making framework
    • Financing
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Videos
    • Reports
    • Past projects
  • News
    • Press releases
    • Perspectives
  • About us
    • Donors
    • Contact us
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Tools for advocates
    • Propose a project
  • Home
  • Resources
  • Past projects

Past projects

  • University of Oxford AMA-1(FMP2.1)/AS01B
    2014 - 2015
    Translational project
  • QIMR Berghofer Medical Research Institute Experimental Plasmodium vivax transmission to Anopheles (EVITA)
    2013 - 2014
    Translational project
  • Fraunhofer Center for Molecular Biotechnology Pfs25-VLP/Alhydrogel
    2013 - 2014
    Translational project
  • University of Oxford ChAd63-MVA ME-TRAP/ChAd63 CS and ChAd63-MVA ME-TRAP/ChAd63-MVA AMA-1
    2012 - 2013
    Translational project
  • University of Oxford ChAd63 CS and ChAd63-MVA CS
    2011 - 2012
    Translational project
  • Janssen (formerly Crucell) Ad35.CS/Ad26.CS
    2011 - 2012
    Translational project
  • Walter Reed Army Institute of Research (WRAIR) VMP001/AS01B
    2010 - 2011
    Translational project
  • Sanaria PfSPZ
    2009 - 2010
    Translational project
  • United States National Institute of Allergy and Infectious Diseases AMA1-C1/ISA 720
    2007 - 2009
    Translational project
  • QIMR Berghofer Medical Research Institute MSP2-C1/ISA 720
    2008 - 2009
    Translational project

Pages

  • 1
  • 2
  • next ›
  • last »

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2023 PATH
Website by Manta Ray Media